BRYHALI (halobetasol propionate)
BRYHALI is a topical lotion used to manage plaque psoriasis in adult patients. As a corticosteroid, it helps patients with the skin symptoms associated with this condition. It is applied directly to the skin to address the underlying issues that cause plaque formation.
How BRYHALI Works
This medication works by influencing cellular signaling, immune function, and protein regulation within the body. It also plays a role in managing inflammation, though the exact way these actions improve plaque psoriasis is not yet fully understood.
Details
- Status
- Prescription
- First Approved
- 2018-11-06
- Patent Cliff
- 2031
- Routes
- TOPICAL
- Dosage Forms
- LOTION
BRYHALI Approval History
What BRYHALI Treats
1 indicationsBRYHALI is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Plaque Psoriasis
BRYHALI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to BRYHALI
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05608499 results posted | GCO-22-0955 | Ph 3 | terminated | Duobrii Treatment of Acne Keloidalis Nuchae (AKN) |
| NCT03298581 | 71542610 | Ph 2 | withdrawn | Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BRYHALI FDA Label Details
Indications & Usage
FDA Label (PDF)BRYHALI is indicated for the treatment of Plaque Psoriasis.
BRYHALI Patents & Exclusivity
Patents (6 active)
Pro Intelligence Preview
Deep insights for BRYHALI
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2031
- • 6 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.